• Je něco špatně v tomto záznamu ?

Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases

L. Zisser, J. Yu, A. Oszwald, T. Wollenweber, E. Kretschmer-Chott, B. Grubmüller, G. Kramer, SF. Shariat, M. Mitterhauser, C. Vraka, M. Hacker, AR. Haug, S. Rasul

. 2022 ; 43 (11) : 1113-1120. [pub] 20220919

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032834

OBJECTIVE: [ 177 Lu]Lu-PSMA radioligand therapy (PSMA-RLT) is a promising therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) and offers a survival benefit particularly to patients with only lymph node metastases. We therefore sought to evaluate the clinical outcome of this therapy in such a cohort. METHODS: Of all prostate cancer patients admitted to our department between September 2015 and March 2019 to receive 1-4 courses of PSMA-RLT (each course consisted of three cycles of highly standardized PSMA-RLT every 4 weeks), only 10 consecutive men were found to have nodal metastases only and were analyzed retrospectively. RESULTS: Nine out of 10 patients responded to their first PSMA-RLT course with a mean prostate-specific antigen (PSA) decline of 71.8 ± 25.2%, seven of them demonstrated a PSA decline of ≥50%. Collectively, seven of eight patients responded to further PSMA-RLT courses with a total PSA reduction of 59.8 ± 30.0%, five of which showed a PSA reduction of ≥50%. One patient experienced complete remission. Median progression-free survival was 85 weeks (range 14-255 weeks) and median overall survival was not reached during the median observation time of 209 weeks (30-298 weeks). Univariate Cox-regression identified initial PSA decline as the only predictive parameter for progression-free survival ( P = 0.047). CONCLUSION: mCRPC patients with only lymph node metastases showed favorable survival and excellent response to PSMA-RLT, leading to transient partial remission of the disease in most of them.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032834
003      
CZ-PrNML
005      
20230131150943.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MNM.0000000000001611 $2 doi
035    __
$a (PubMed)36120814
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Zisser, Lucia $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
245    10
$a Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases / $c L. Zisser, J. Yu, A. Oszwald, T. Wollenweber, E. Kretschmer-Chott, B. Grubmüller, G. Kramer, SF. Shariat, M. Mitterhauser, C. Vraka, M. Hacker, AR. Haug, S. Rasul
520    9_
$a OBJECTIVE: [ 177 Lu]Lu-PSMA radioligand therapy (PSMA-RLT) is a promising therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) and offers a survival benefit particularly to patients with only lymph node metastases. We therefore sought to evaluate the clinical outcome of this therapy in such a cohort. METHODS: Of all prostate cancer patients admitted to our department between September 2015 and March 2019 to receive 1-4 courses of PSMA-RLT (each course consisted of three cycles of highly standardized PSMA-RLT every 4 weeks), only 10 consecutive men were found to have nodal metastases only and were analyzed retrospectively. RESULTS: Nine out of 10 patients responded to their first PSMA-RLT course with a mean prostate-specific antigen (PSA) decline of 71.8 ± 25.2%, seven of them demonstrated a PSA decline of ≥50%. Collectively, seven of eight patients responded to further PSMA-RLT courses with a total PSA reduction of 59.8 ± 30.0%, five of which showed a PSA reduction of ≥50%. One patient experienced complete remission. Median progression-free survival was 85 weeks (range 14-255 weeks) and median overall survival was not reached during the median observation time of 209 weeks (30-298 weeks). Univariate Cox-regression identified initial PSA decline as the only predictive parameter for progression-free survival ( P = 0.047). CONCLUSION: mCRPC patients with only lymph node metastases showed favorable survival and excellent response to PSMA-RLT, leading to transient partial remission of the disease in most of them.
650    _2
$a dipeptidy $x terapeutické užití $7 D004151
650    _2
$a heterocyklické sloučeniny monocyklické $x terapeutické užití $7 D006573
650    _2
$a lidé $7 D006801
650    _2
$a lutecium $x terapeutické užití $7 D008187
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a mužské pohlaví $7 D008297
650    12
$a prostatický specifický antigen $7 D017430
650    12
$a nádory prostaty rezistentní na kastraci $x patologie $7 D064129
650    _2
$a radionuklidy $7 D011868
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
700    1_
$a Yu, Josef $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
700    1_
$a Oszwald, André $u Department of Pathology
700    1_
$a Wollenweber, Tim $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
700    1_
$a Kretschmer-Chott, Elisabeth $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
700    1_
$a Grubmüller, Bernhard $u Department of Urology, Medical University of Vienna, Vienna, Austria
700    1_
$a Kramer, Gero $u Department of Urology, Medical University of Vienna, Vienna, Austria
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
700    1_
$a Mitterhauser, Markus $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine $u Ludwig Boltzmann Institute Applied Diagnostics
700    1_
$a Vraka, Chrysoula $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
700    1_
$a Hacker, Marcus $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
700    1_
$a Haug, Alexander R $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine $u Christian Doppler Laboratory for Applied Metabolomics (CDL AM), Medical University of Vienna, Vienna, Austria
700    1_
$a Rasul, Sazan $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine
773    0_
$w MED00010325 $t Nuclear medicine communications $x 1473-5628 $g Roč. 43, č. 11 (2022), s. 1113-1120
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36120814 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131150939 $b ABA008
999    __
$a ok $b bmc $g 1891523 $s 1184169
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 43 $c 11 $d 1113-1120 $e 20220919 $i 1473-5628 $m Nuclear medicine communications $n Nucl Med Commun $x MED00010325
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace